Table 3. Patient outcome for gemcitabine-refractory patients treated with 3-aminopyridine-2-carboxaldehyde thiosemicarbazone.
| Outcome | Estimate (95% CI)a |
|---|---|
| Best Objective Response | |
| Evaluable | 13 |
| CR | 0% (0–23%) |
| PR | 0% (0–23%) |
| SD | 15% (3–43%) |
| PD | 85% (50–94%) |
| Time to Progression | |
| Progressions | 12 |
| Median | 1.8 mos. (1.3–1.8 mos.) |
| Percent Progression-Free | |
| 3 mos. | 9% (1 –57%) |
| 4 mos. | 9% (1 – 57%) |
| 6 mos. | 9% (1 – 57%) |
| Survival | |
| Deaths | 13 |
| Median | 3.5 mos. (1.9–3.8 mos.) |
| Percent Alive | |
| 3 mos. | 64% (44–95%) |
| 4 mos. | 21% (8–58%) |
| 6 mos. | 7% (1–47%) |
| 9 mos. | 7% (1–47%) |
| 12 mos. | 7% (1–47%) |
| 15 mos. | 7% (1–47%) |
Abbreviations: CR complete response, PR partial response, SD stable disease, PD progressive disease, mos. Months
a
Kaplan–Meier method